Schizoaffective Disorders Completed Phase 2 Trials for Icosapent (DB00159)

Also known as: Schizoaffective disorder / Schizophrenia schizoaffective / Schizoaffective psychosis / Schizo-affective type schizophrenia

IndicationStatusPhase
DBCOND0033299 (Schizoaffective Disorders)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00167310Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid SupplementationTreatment